Drug Use Investigation for HEPSERA (Adefovir) Tablet

GlaxoSmithKline436 enrolled

Overview

This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data among subjects with chronic hepatitis B and hepatic cirrhosis B who is treated with adefovir tablets.

Study Type

OBSERVATIONAL

Enrollment

436

Conditions

Hepatitis B

Interventions

Adefovir tabletsDRUG

Administered according to the prescribing information in the locally approved label by the authorities.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with chronic hepatitis B or hepatic cirrhosis B * Subjects treated with adefovir tablets Exclusion Criteria: * None

Outcomes

Primary Outcomes

The incidence of adverse drug reactions

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.